Clearside Biomedical Added to the Nasdaq Biotechnology Index

Rhea-AI Summary

Clearside Biomedical (Nasdaq: CLSD) has been added to the Nasdaq Biotechnology Index, effective December 20, 2021. This index tracks biotechnology and pharmaceutical securities on Nasdaq, requiring companies to meet specific eligibility criteria, including market capitalization and trading volume. Clearside is known for its innovative delivery of therapies to the back of the eye via the suprachoroidal space (SCS), with its first product, XIPERE, recently approved by the FDA. The addition to the index underscores Clearside's standing in the biopharmaceutical sector.

Positive

• Inclusion in the Nasdaq Biotechnology Index, enhancing visibility among investors.
• Recent FDA approval of XIPERE for suprachoroidal use, indicating successful product development.

Negative

• None.

ALPHARETTA, Ga., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®), announced today that the Company will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.

The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market^® (Nasdaq^®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December.

About Clearside Biomedical

Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS^®). Clearside’s SCS injection platform, utilizing the Company’s proprietary SCS Microinjector^®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector and strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. Clearside’s first product, XIPERE^™ (triamcinolone acetonide injectable suspension) for suprachoroidal use, was approved by the U.S. Food and Drug Administration in October 2021. For more information, please visit www.clearsidebio.com.

Investor and Media Contacts:

Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206

Source: Clearside Biomedical, Inc.

FAQ

When will Clearside Biomedical be added to the Nasdaq Biotechnology Index?

Clearside Biomedical will be added to the Nasdaq Biotechnology Index effective December 20, 2021.

What is the significance of Clearside Biomedical joining the Nasdaq Biotechnology Index?

Joining the Nasdaq Biotechnology Index enhances Clearside's visibility and credibility among investors in the biotech sector.

What is the first product approved by Clearside Biomedical?

Clearside's first product, XIPERE, was approved by the FDA in October 2021.

What is Clearside Biomedical known for?

Clearside Biomedical specializes in delivering therapies to the back of the eye through the suprachoroidal space (SCS) using its proprietary injection platform.

What are the eligibility requirements for the Nasdaq Biotechnology Index?

Companies must meet criteria including minimum market capitalization, average daily trading volume, and public company seasoning.